Efficacy and safety of PAH-specific therapy in pulmonary arterial hypertension: a meta-analysis of randomized clinical trials

Background

Previous meta-analyses of PAH-specific therapy for pulmonary arterial hypertension (PAH) pooled PAH-specific combination therapy and monotherapy together. The flaw might threaten the authenticity of their findings.

Methods

PubMed, Embase, and the Cochrane Library were searched for randomized controlled trials (RCTs) that evaluated any PAH-specific medications in the treatment of PAH. We calculated odds ratio (OR) with 95% confidence intervals (CIs) for dichotomous data and standardized mean differences for continuous data.

Results

In total, 35 RCTs involving 6,702 patients were included. In monotherapy vs placebo/conventional therapy, significance was obtained in mortality reduction (OR:0.50; 95%CI:0.33-0.76; P=0.001), six-minute walk test (6MWD) (MD:31.10m; 95%CI: 25.40 to 36.80; P Conclusions

from #Medicine via ola Kala on Inoreader http://ift.tt/1oFrtqH
via IFTTT